Used For:

• Treatment of HIV-1 infection in adults and adolescents (≥12 years and weighing ≥35 kg) as part of combination antiretroviral therapy (cART).Prevention of mother-to-child transmission of HIV (in combination therapy, under medical supervision).May be used in HIV pre-exposure prophylaxis (PrEP) in certain regimens (off-label, per guidelines).

Adult Dosage:

• Recommended dose: 1 tablet once daily, orally, with or without food.Must always be taken in combination with other antiretroviral agents, not as monotherapy.No dose adjustment is usually needed for mild to moderate renal impairment.

Pack:

• 30

Contraindications:

• Known hypersensitivity to emtricitabine, tenofovir alafenamide, or any excipient in the tablet.Severe renal impairment (eGFR <15 mL/min) unless under specialist supervision.Hepatitis B virus (HBV) infection: discontinuation can cause severe acute exacerbation — caution needed.

Side Effects:

• Common Side EffectsGastrointestinal: Nausea, diarrhea, abdominal painCNS: Headache, dizziness, insomniaMetabolic: Fatigue, mild weight lossDermatologic: Rash, hyperpigmentation of palms or soles (rare)Serious / Rare Side EffectsLactic acidosis and severe hepatomegaly with steatosis (rare but life-threatening)Renal toxicity: Fanconi syndrome, renal failure (rare, usually in predisposing conditions)Bone mineral density reduction (TAF has lower risk than Tenofovir Disoproxil Fumarate [TDF], but monitoring may be needed)Exacerbation of hepatitis B if therapy is stopped abruptly

Precautions:

• HIV treatment: Must always be part of a combination therapy regimen, not used alone.Renal function: Monitor serum creatinine and eGFR periodically.Liver function: Monitor in patients with HBV or HCV co-infection.Pregnancy and breastfeeding: Can be used if the benefit outweighs the risk; monitor infants for HIV exposure.Resistance: Ensure adherence to avoid drug resistance.Drug interactions: Caution with nephrotoxic drugs (NSAIDs, aminoglycosides) or other antiretrovirals.